Assessing the effectiveness of the TURALIO (pexidartinib) risk evaluation and mitigation strategy program: patient knowledge, attitudes, and behavior survey (2020–2024)

Charles Dharmani, Oluwatosin Fofah, Margaret Wooddell, Janet L. Ramsey, Michele Riggen · 2026

Read Assessing the effectiveness of the TURALIO (pexidartinib) risk evaluation and mitigation strategy program: patient knowledge, attitudes, and behavior survey (2020–2024) by Charles Dharmani, Oluwatosin Fofah, Margaret Wooddell, Janet L. Ramsey, Michele Riggen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13536961.txt.

Description

Charles Dharmani and colleagues assess a safety program for a joint tumor drug with liver risk in a 2026 survey series from 2020 to 2024. Pexidartinib treats a rare joint lining tumor yet can seriously harm the liver, so use requires enrollment, teaching, and regular liver checks. Four voluntary survey waves asked patients and caregivers about liver risk knowledge and monitoring duties, drawing 239 completed replies in total.

Single knowledge items scored high throughout. Understanding of liver harm stayed at or above the preset success level in each wave, while understanding of monitoring improved over time and reached a perfect share in one wave. Combined understanding of both messages dipped below the level in three waves. The authors conclude that knowledge stayed broadly steady and supports program effectiveness.

Catalog record

CREATORCharles Dharmani, Oluwatosin Fofah, Margaret Wooddell, Janet L. Ramsey, Michele Riggen
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50279
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13536961

Browse the full library · About the Tower of Babel